1. Mr. Alfred E. Mann , 88 years old, has met his long term dream objective with this approval.
2. The product market for rapid response insulin delivery mechanism is about $6 billion worldwide.
3. Since this is likely to be the most rapid response insulin approved for at least a while, it is highly likely to have about half the world market by the end of 18 months.
4. It has two major competitors in the fast acting insulin market but both have slower acting products.
5. One of the competitors products will become generic soon and that company will be nearly desperate to find alternative blockbusters.
6. There are at least 4 major large cap pharmaceutical companies with core interests in diabetes insulin market and they include ABT LLY SNY MRK and several others.
7. They all know the situation and the fact that MNKD is currently priced far below its revenue probability (price:sales ratio will likely be 7:1 meaning the market cap will likely be 7 times the market or $21 billion).
8. Diabetics will strongly prefer Afrezza over legacy rapid delivery insulins because they hate those needles injected in the stomach at every meal. Inhaled insulin is far more effective, rapid at sugar control.
I think another reason is Mann's track record. He invents, develops, and sells. Why would he stop now, at 88? Because he wants to stick around and watch this drug change the world over the next 5 years? He knows the score...he may not be around in 5 years. Why not sell, and ride off into the sunset with his last and greatest success?